Tuberculosis Flashcards

1
Q

Trends in TB

A

• Worldwide trends
o Infects 1/3 of world’s population
o Most cases occur in SE Asia, sub-Saharan Africa, and Eastern Europe

• National trends
o Greatest number of TB cases:
• In foreign-born persons from high prevalence countries
• Racial/ethnic minorities (African-Americans)
• Certain populations (living in congregate settings like corrections, long term care facilities)

• Wisconsin Trends
o 70 cases in 2011 (>40% were in Milwaukee county)
o >50% cases were in persons born outside U.S.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Transmission of TB

A

o Humans are only natural reservoir for M. tuberculosis
o Spread person-to-person by aerosols
o Equally affects males and females

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Populations with increased risk of TB

A
  • Elderly
  • Infants
  • Immunocompromised (especially with HIV = TB is leaded killer)

Patients at high risk:
• AFB smear positive (because need 10^5 organisms for positive test)
• Cavitary lung disease (~10^9-10^12 organisms)
• Laryngeal disease
• Cough and fail to cover mouth
• Procedures that increase aerosolization
• Untreated disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the structure and properties of TB

A

• Structure
o Unusual waxy coating on cell surface
o Made of mycolic acid (>60%)
• High lipid content = impermeable to usual stains (Gram stain)
o Also includes: sulfolipids, LAM (lipoarabinomannan)

• Properties
o Intracellular pathogen
o Ingested by macrophages but not killed
o Inhibits phagolysosome fusion → prevents acidification of vacuole → can multiply within macrophages
o Obligate aerobe
o Slow growing (24 hour generation time)
o Resistant to drying and common disinfectants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Virulence mechanisms of TB

A

o Key virulence = ability to multiply in macrophages
o Cell wall components disrupt phagosome-lysosome interactions → interfere with oxidative killing
o LAM induces macrophages → produce TNF-α → fever, weight loss, tissue damage
o Increases IL-10 production → immuosuppression
o Cord factor = surface glycolipid only in virulent strains
• Triggers TH1 response, enhances macrophage survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the transmission of tuberculosis infection

A

o Reservoir: people with cavitary lung lesions with large amounts of M. tuberculosis
o Into environment via coughing or sneezing
o Transferred when another person inhales aerosolized droplet nuclei
o Small droplet nuclei (1-5 μm) may reach alveoli in mid to lower lobes → infection

•	Likelihood of infection depends on:
o	Number of organisms expelled into air
o	Concentration of organisms in air (influenced by room size, ventilation)
o	Length of time exposed
o	Immune status of exposed person
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the pathogenesis of tuberculosis infection

A

o Primary TB/ TB infection = response in person who has not been previously infected
• Inhaled droplet nuclei (containing bacilli) are deposited in lung
• Some bacilli are taken up by alveolar macrophages:
Outcome:
• Myobacteria can multiply in macrophages and alveolar spaces
• Circulating macrophages can carry organisms to distant sites (lymph nodes, bloodstream) → antigen is presented to helper T cells
• Silent bacteremia = carries organisms to body sites

• Results:
• Unrestrained replication in initial and metastatic foci
• Elicits CMI response
• Activated T cells circulate → Delayed type hypersensitivity
o Surround bacilli
o Form granulomas
o Stop further multiplication and spread
Granuloma fates:
o Most heal through fibrosis an calcification
• Bacilli slowly die
o Well-oxygenated sites = bacilli may remain viable even if walled off
• Source of disease later on
o At primary sites in lung and regional nodes:
• Central necrosis lesion, surrounded by macrophages and T cells (Ghon complex/ primary complex)
• Visible on chest x-ray

  • Overall = infected by not infectious to others (Latent TB infection)
  • 10% chance over lifetime infection will proceed to disease (if not treated with chemoprophylaxis)
  • Highest risk is within first 2 years (50% of cases occur)

Active disease (symptoms present)
• Due to a compromise of CMI = dormant bacilli begin to replicate
• Can manifest at one site or as a disseminated disease
• Reactivation often occurs in upper, well-oxygenated lobes of lung
• Lesions become necrotic, caseate, and liquefy
• Form cavities → can erode through bronchial walls
• Visible on chest x-ray
• Person is infectious to others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Signs and symptoms of TB infection

A

From intense cellular response
• Release of many cytokines (especially IL-1 and TNF-α)
• Cough (possible producing blood-tinged sputum)
• Weight loss
• Night sweats
• Fever and chills

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Extrapulmonary TB

A
o	From contiguous spread or lymphohematogenous dissemination from lung
Results in TB in extrapulmonary site: 
•	Bones and joints
•	Pleura
•	Lymphatic system
•	GU tract
•	CNS
•	GI tract
More common in children and immunocompromised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Disseminated TB (military TB)

A

o Serious form
o Spread via blood to multiple sites throughout body
o Organs are seeded with millet-like lesions
o Commonly seen in people co-infected with HIV; young children
o High mortality if not quickly diagnosed and treated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Explain the significance of co-infection with HIV and the mycobacteria involved.

A

TB = most common HIV-associated opportunistic disease
o Major cause of death of people with HIV/AIDS
HIV = strongest risk factor for latent TB to progress to active disease
o HIV modifies clinical TB presentation
o Increased frequency of radiographically and atypical pulmonary TB, extrapulmonary and disseminated disease

Complicated treatment of TB/HIV
o Many drug-drug interactions
o Development of IRIS (Immune Reconstitution Inflammatory Syndrome:
• Improvement of CD4 cells
• Able to react to TB
• Result: pathologically inflammatory response

At risk for developing Mycobacterium avium complex (MAI, or MAC)
o Mycobacterial disease
o Caused by mycobacteria in environment (water, soil, food)
o Usually only infects birds
o Rarely causes disease in normal individuals
o Acquired primarily through respiratory tract; also through GI tract
o Widespread dissemination throughout body
• Especially liver, spleen, bone marrow, and intestines
o In HIV patients = results in chronic wasting disease
• Nonspecific symptoms
• Persistent fever, night sweats, fatigue, weight loss
• Intestinal involvement → abdominal pain and chronic watery diarrhea
o Diagnose with blood cultures
o Treatment: second-line anti-TB drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Discuss why young children need to be identified soon after contact with an individual who has active disease, including predisposing factors.

A

• Increased risk of developing severe disease (weeks to months of infection)
• Predisposing factors:
o Close contact with adult with active TB
o Close contact with high-risk adult
o Foreign-born or travel to TB-prevalent country
o Chronic conditions:
• Diabetes
• Malnutrition
• HIV
• Increased risk for developing TB meningitis
• Leads to deafness, blindness, paralysis, mental impairments
• Immunodeficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

List the laboratory tests available to diagnose M. tuberculosis.

A
Acid-Fast Stain (Ziehl-Neelsen stain, Auramine-Rhodamine stain)
Nucleic acid amplification 
Culture
Drug susceptibility testing
TB skin testing
TB blood tests (IGRA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Acid-Fast Stains

A

o To detect acid fast bacilli = need 5,000-10,000 bacili/ml
o Only 50-80% patients with TB have a positive smear
o If positive smear = assumed to have infectious TB

Ziehl-Neelsen stain
• Acid-fast because retain carbol fuschsin stain even after decolorizing with acid alcohol
• Appear = magenta rods on blue background

Auramine-Rhodamine Stain
• Fluorescent dye followed by acid decolorization
• Mycobacteria fluoresce bright yellow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nucleic acid amplification

A

(M. tuberculosis direct test)
o Available for respiratory specimens
o Detects TB genetic material

o Performed on:
• All smear-positive specimens
• Specimens from patients with symptoms of clinical TB (even if smear-negative)

o Advantages:
• Results within 24 hours

o Disadvantages:
• Low sensitivity in smear-negative patients
• No viable organisms available for susceptibility testing
• Not applicable in resource limited stings
o A negative test does not exclude TB diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TB culture Test

A

o Requires 6-8 weeks
o Newer methods only need 7 days
o Identify using biochemical reactions (M. tb and M. simiae are only niacin test [+] of slow-growing mycobacteria), chromatographic analysis of mycolic acid, nuclei acid probes

14
Q

TB Drug susceptibility Testing

A

o To first line anti-TB drugs (isoniazid, rifampin, ethanbutol, pyrazinamide)
o May take 5 weeks before know TB identification and susceptibility by traditional techniques

Resistance classification:
• Drug-resistant: to at least one of first-line anti-TB drugs
• Multi-drug resistant (MDR-TB): to at least isoniazid and rifampin
• Longer treatment (~2 years)
• More drugs and toxicity
• Increased costs
• Poorer outcomes (higher mortality, significant probability of surgery, chronic renal/neurologic toxicities)
• Extensively drug-resistant (XDR-TB): to all of first line anti-TB agents, fluoroquinolones, and at least one of three injectable 2nd line anti-TB drugs

Molecular drug-resistance tests
• Results within 1-2 days
• Sensitivity of 95% to detect rifampin resistance
• Moderate sensitivity of 85% for isoniazid resistance

14
Q

TB skin testing

A

o Still gold standard

Process:
• Intradermal injection of purified protein derivative (PPD)
• Causes localized inflammatory response when infected with TB
• Measure induration (palpable raised area; NOT erythema) 48-72 hours after injection
• Record induration in mm (if no reaction = 0 mm)

Limitations:
Problems with implementation
•	Requires patient follow-up
•	Significant inter-rater variability
•	Prone to rounding up errors 
Prone to false-negatives (reduced sensitivity) 
•	Anergy
•	Booster phenomenon
•	Active TB (IL-10 effect)
Prone to false positives (reduced specificity)
•	Due to rounding up error
•	Due to endemic NTM
•	Due to prior BCG vaccination
14
Q

TB blood tests

A

(interferon-gamma release assays = IGRAs)

Process:
• Collect peripheral blood sample
• Incubate with mycobacterial antigens (present in TB but not BCG vaccine)
• If infected = WBC’s release INF-γ
• Assess amount of INF-γ released using ELISA

Advantages over TB skin testing
• Increased specificity
• More sensitive to identify recent infection
• Only one visit required
• Little inter-observer variability
• No booster responses with repeated testing
• Not affected by prior BCG vaccination

Disadvantages:
• Cannot distinguish between latent or active TB
• Still need additional tests
• Expense
• Can cross react with several non-TB mycobacterial species
• M. marinum, M. kansasii
• Only moderate agreement between different IGRA assays
• Moderately high rates of indeterminate results in children and people with advanced immunosuppression
• Variable INF-γ levels → high frequency of conversions/reversions in people who get tested often
• Not validated to detect remote TB exposure (theoretical concern about impaired sensitivity)

14
Q

Explain the rationale of targeted tuberculin testing

A

o Skin testing only in well-defined groups:
• Due to chances of false-positives

At higher risk for TB exposure or infection
• Close contacts of person with TB
• Foreign-born people from high TB prevalence areas
• Residents and employees of high risk congregate settings
• Health care workers
• High risk racial or ethnic minorities
• Infants and youth exposed to high-risk adults
• Persons who abuse drugs or alcohol
• People with chest radiographs suggestive of prior TB

At higher risk for TB disease once infected
• HIV infection
• Recently infected with TB
• Medical conditions known to increase risk
• History of inadequately treated TB
• Children less than 4 years old

14
Q

Why does TB reaction occur?

A

o Type IV hypersensitivity reaction (DTH)
o Indirectly detects latent TB infection
Biphasic cellular response
1) Non-specific
2) Specific:
• Neutrophils → CD4+ cells → macrophages
• CD4+ cells predominant; mostly memory cells
• Local production of IFN-γ, TNF-α, TNF-β
• Stimulate endothelial changes → increase permeability → erythema and induration

14
Q

Explain the booster effect in TB skin testing

A

o A false-negative skin test in people with latent TB for many years may occur
o TB test stimulates (boosts) immune system of someone previously infected
o Result: positive/boosted reaction to subsequent tests
• May be interpreted as a new infection
o Prevent:
• Retest non-reactors 1-3 weeks after 1st test
• If 2nd test is positive = boosting, not a recent infection (takes >3 weeks to convert a new infection)

14
Q

Describe false-negatives with TB skin testing

A
  • Cutaneous anergy (with weakened immune system)
  • Recent TB infection (within 8-10 weeks)
  • Very old TB infection (many years)
  • Very young age (< 6 months)
  • Recent live-virus vaccination (measles)
  • Overwhelming TB disease
  • Some viral illnesses
  • Incorrect administration of skin test
  • Incorrect interpretation of reaction
14
Q

Describe false-positives with TB skin testing

A
  • Exposure to environmental mycobacteria
  • Previous BCG vaccination
  • Incorrect skin test administration
  • Incorrect interpretation of reactions
14
Q

Explain the importance of timely reporting of all TB cases (or suspected cases) to local public health departments.

A
  • Reported within 24 hours
  • Notify state epidemiologist
  • Failure to report → delays in instituting treatment plan and protecting contacts
14
Q

Discuss the role of the non-tuberculous mycobacteria in human disease.

A

Mycobacterium leprae
o Causes leprosy
o Chronic granulomatous disease of peripheral nerves and superficial tissues

Environmental mycobacteria
o	AKA non-tuberculous mycobacteria or atypical mycobacteria
o	Includes: M. avium, M. gordonae, M. chelonae
o	Acquired by aspiration or inoculation 
o	Common source = water
o	No person to person transmission 
o	Resistance to many 1st line anti-TB drugs
o	Common manifestations:
•	Pulmonary disease
•	Lymphadenitis
•	Skin/soft tissue infection 
•	Disseminated infection
Diagnose:
•	Isolation 
•	Identification of pathogen by smears, culture, nucleic acid tests
Treatment
•	Multi-drug regimen
14
Q

Explain the concepts that are important in effective treatment of tuberculosis disease and latent infection with antimicrobials.

A

• ALWAYS multi-drug treatment
o Use at least 4 drugs
o Add more if resistance epidemiologically indicated
• Utilize rapid resistance testing for rifampin and INH
• Monitor adherence
• Assess response at 2 months
• Continue for appropriate length of time
o Prolonged therapy (6-9 months)

Susceptible TB:
o Non-infectious 2-3 weeks after treatment
o Cure rate > 90%
Resistant TB
o Non-infectious after several weeks- months
o Cure rate < 50%
Latent TB
o Physical exam and chest x-ray
o Standard treatment: isoniazid for 9 months
o Alternative treatment: rifampin for 4 months; isoniazid-ripapentene 1x/week for 12 weeks